印度服务公司将于2025年11月11日在全国范围内推出白血病和胆管癌症的补贴IDH1/2测试. Servier India launches subsidized IDH1/2 testing for leukemia and bile duct cancer nationwide on Nov. 11, 2025.

印度服务社与MedGenome和Strand生命科学公司合作,于2025年11月11日发起生物标志测试倡议,向印度全国提供补贴的IDH1 和 IDH2 突变测试,以检测急性流血性白血病和霍乱。 Servier India, in partnership with MedGenome and Strand Life Sciences, has launched a biomarker testing initiative on November 11, 2025, offering subsidized IDH1 and IDH2 mutation testing for acute myeloid leukaemia and cholangiocarcinoma across India. 政府保健服务提供者可以免费进行检测,而私营部门的获取则通过降低成本得到支持。 Free testing is available to government healthcare providers, while private sector access is supported through reduced costs. 该方案旨在将分子诊断扩大到城市中心之外,改进早期诊断,支持改善治疗结果。 The program aims to expand molecular diagnostics beyond urban centers, improve early diagnosis, and support better treatment outcomes. 它是Servier的 " 服务护理 " 倡议的一部分,该倡议在允许的情况下提供财政援助、免费药品和诊断支持。 It is part of Servier’s ‘Servier Care’ initiative, which provides financial aid, free medication, and diagnostic support where permitted.